Saurabh Zanwar1, Vikas Ostwal2, Arvind Sahu1, Deepak Jain3, Anant Ramaswamy1, Avanish Saklani3, Mukta Ramadwar4, Nitin Shetty5, Shailesh V Shrikande3. 1. Department of Medical Oncology, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai, 400 012, India. 2. Department of Medical Oncology, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai, 400 012, India. dr.vikas.ostwal@gmail.com. 3. Department of Surgical Oncology, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai, 400 012, India. 4. Department of Pathology, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai, 400 012, India. 5. Department of Interventional Radiology, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai, 400 012, India.
Abstract
INTRODUCTION: There is scarce data relating to methods to improve sphincter preservation in rectal gastrointestinal stromal tumor (GIST). Increasing the duration of neoadjuvant (NA) imatinib resulting in improved sphincter preservation rate has not been established. This retrospective analysis looks at the rates of sphincter preservation in rectal GIST with NA imatinib and effect of duration of NA imatinib on the same to find out optimum duration of NA with respect to sphincter preservation in rectal GIST patients. METHODS: Twenty-three cases of GIST of lower third of rectum were treated at our centre from 2005 till 2015. NA imatinib was used in a dose of 400 mg. Response evaluation was done every 3 months with a pelvic magnetic resonance imaging. Surgical management was determined by a team of experienced gastrointestinal oncosurgeons. RESULTS: Five patients underwent upfront surgery which included local resection in four patients and abdominoperineal resection in one patient. NA imatinib was used in 69.5 % (16/23) patients. Median duration of NA imatinib was 15 months (3-84 months). Amongst who underwent a sphincter-salvage surgery median duration of NA imatinib was 13 months whereas 18 months in patients who required a sphincter-sacrificing surgery (p = 0.683). The radiologic response included partial response in 75 % (12/16) patients, stable disease in 18.7 % (3/16) and one with progressive disease. Definitive surgical resection was possible in 13 patients (81.3 %) after NA imatinib. Median progression-free survival (PFS) was 120 months in the whole cohort whereas median overall survival (OS) was not reached. Four-year estimated PFS and OS was 81 % and 100 %, respectively. Median disease-free survival in upfront surgery group vs. neoadjuvant imatinib group was 70 vs. 120 months, respectively (p = 0.039). CONCLUSION: Neoadjuvant imatinib appears to be a useful option in improving chances of sphincter preservation without adversely affecting the outcome. Use of neoadjuvant imatinib leads to improvement in progression-free survival in patients with GIST of lower third of the rectum.
INTRODUCTION: There is scarce data relating to methods to improve sphincter preservation in rectal gastrointestinal stromal tumor (GIST). Increasing the duration of neoadjuvant (NA) imatinib resulting in improved sphincter preservation rate has not been established. This retrospective analysis looks at the rates of sphincter preservation in rectal GIST with NA imatinib and effect of duration of NA imatinib on the same to find out optimum duration of NA with respect to sphincter preservation in rectal GIST patients. METHODS: Twenty-three cases of GIST of lower third of rectum were treated at our centre from 2005 till 2015. NA imatinib was used in a dose of 400 mg. Response evaluation was done every 3 months with a pelvic magnetic resonance imaging. Surgical management was determined by a team of experienced gastrointestinal oncosurgeons. RESULTS: Five patients underwent upfront surgery which included local resection in four patients and abdominoperineal resection in one patient. NA imatinib was used in 69.5 % (16/23) patients. Median duration of NA imatinib was 15 months (3-84 months). Amongst who underwent a sphincter-salvage surgery median duration of NA imatinib was 13 months whereas 18 months in patients who required a sphincter-sacrificing surgery (p = 0.683). The radiologic response included partial response in 75 % (12/16) patients, stable disease in 18.7 % (3/16) and one with progressive disease. Definitive surgical resection was possible in 13 patients (81.3 %) after NA imatinib. Median progression-free survival (PFS) was 120 months in the whole cohort whereas median overall survival (OS) was not reached. Four-year estimated PFS and OS was 81 % and 100 %, respectively. Median disease-free survival in upfront surgery group vs. neoadjuvant imatinib group was 70 vs. 120 months, respectively (p = 0.039). CONCLUSION: Neoadjuvant imatinib appears to be a useful option in improving chances of sphincter preservation without adversely affecting the outcome. Use of neoadjuvant imatinib leads to improvement in progression-free survival in patients with GIST of lower third of the rectum.
Authors: Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss Journal: Hum Pathol Date: 2002-05 Impact factor: 3.466
Authors: Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden Journal: Ann Surg Oncol Date: 2013-06-13 Impact factor: 5.344
Authors: Jurriën Stiekema; Sabrine Kol; Annemieke Cats; Amir T Yazdi; Frits van Coevorden; Johanna W van Sandick Journal: Am J Clin Oncol Date: 2015-10 Impact factor: 2.339
Authors: Mohamad Farid; Marcus Jin Fu Lee; Min Hoe Chew; Whee Sze Ong; Alisa Noor Hidayah Sairi; Kian Fong Foo; Su Pin Choo; Wen Hsin Koo; Simon Ong; Poh Koon Koh; Richard Quek Journal: Mol Clin Oncol Date: 2012-09-19
Authors: Aurore Blesius; Philippe A Cassier; François Bertucci; Jerome Fayette; Isabelle Ray-Coquard; Binh Bui; Antoine Adenis; Maria Rios; Didier Cupissol; David Pérol; Jean-Yves Blay; Axel Le Cesne Journal: BMC Cancer Date: 2011-02-15 Impact factor: 4.430